A securities class action lawsuit has been filed against Regenxbio Inc. on behalf of investors who purchased shares between February 9, 2022 and January 27, 2026. The lawsuit alleges that the company made false and misleading statements regarding the efficacy and safety of its RGX-111 trial, concealing material adverse facts. The suit follows a sharp drop in Regenxbio’s stock price after the company revealed an FDA clinical hold on RGX-111 due to discovery of a tumor in a study participant. Investors have until April 14, 2026 to seek lead plaintiff status.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Regenxbio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602161054PRIMZONEFULLFEED9655290) on February 16, 2026, and is solely responsible for the information contained therein.